These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19383846)

  • 1. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
    Pommier Y; Cushman M
    Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
    Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
    Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
    Fox BM; Xiao X; Antony S; Kohlhagen G; Pommier Y; Staker BL; Stewart L; Cushman M
    J Med Chem; 2003 Jul; 46(15):3275-82. PubMed ID: 12852757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
    Cushman M; Jayaraman M; Vroman JA; Fukunaga AK; Fox BM; Kohlhagen G; Strumberg D; Pommier Y
    J Med Chem; 2000 Oct; 43(20):3688-98. PubMed ID: 11020283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
    Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
    Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
    Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).
    Conda-Sheridan M; Reddy PV; Morrell A; Cobb BT; Marchand C; Agama K; Chergui A; Renaud A; Stephen AG; Bindu LK; Pommier Y; Cushman M
    J Med Chem; 2013 Jan; 56(1):182-200. PubMed ID: 23259865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.
    Marzi L; Agama K; Murai J; Difilippantonio S; James A; Peer CJ; Figg WD; Beck D; Elsayed MSA; Cushman M; Pommier Y
    Mol Cancer Ther; 2018 Aug; 17(8):1694-1704. PubMed ID: 29748210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
    Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
    Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
    Strumberg D; Pommier Y; Paull K; Jayaraman M; Nagafuji P; Cushman M
    J Med Chem; 1999 Feb; 42(3):446-57. PubMed ID: 9986716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
    Cinelli MA; Morrell AE; Dexheimer TS; Agama K; Agrawal S; Pommier Y; Cushman M
    Bioorg Med Chem; 2010 Aug; 18(15):5535-52. PubMed ID: 20630766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Topoisomerase I in the Era of Precision Medicine.
    Thomas A; Pommier Y
    Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
    Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
    J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
    Zhang X; Wang R; Zhao L; Lu N; Wang J; You Q; Li Z; Guo Q
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1276-81. PubMed ID: 22079759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
    Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
    Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
    Sooryakumar D; Dexheimer TS; Teicher BA; Pommier Y
    Mol Cancer Ther; 2011 Aug; 10(8):1490-9. PubMed ID: 21636699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dibenzo[c,h][1,5]naphthyridinediones as topoisomerase I inhibitors: design, synthesis, and biological evaluation.
    Kiselev E; Empey N; Agama K; Pommier Y; Cushman M
    J Org Chem; 2012 Jun; 77(11):5167-72. PubMed ID: 22587603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.